Improving Clinically Significant Prostate Cancer Detection with a Multimodal Machine Learning Approach: A Large-Scale Multicenter Study.

Journal: Radiology. Imaging cancer
Published Date:

Abstract

Purpose To develop and prospectively validate a clinical and radiologic model to predict clinically significant prostate cancer (csPCa) using biparametric MRI (bpMRI). Materials and Methods Retrospective data (acquired before March 31, 2022) from 12 medical centers were collected. Radiomic features were extracted from the whole prostate gland using segmentations generated by an automatic deep learning algorithm. A model incorporating bpMRI radiomics, age, prostate-specific antigens, the Prostate Imaging Reporting and Data System (PI-RADS), and the prostate zone lesion location was trained. A retrospective validation set and prospective data (acquired after March 31, 2022) were used to compare PI-RADS scoring (area under the receiver operating characteristic curve [AUC] and specificity at PI-RADS >3). Sensitivity analyses for sequence (T2-weighted, apparent diffusion coefficient, diffusion-weighted imaging) and scanner vendor (GE, Philips, Siemens) were performed, in addition to fairness analyses for relevant categories. Results The retrospective dataset for model development included 7157 male patients (mean age, 64.78 years; 3342 [46.7%] with csPCa), and the prospective dataset for model validation included 1629 patients (mean age, 66.19 years; 592 [36.3%] with csPCa). The multimodal model outperformed PI-RADS in the retrospective (AUC, 0.88 vs 0.80, = .005; specificity of 71% vs 58%, = .002) and prospective validation sets (AUC, 0.91 vs 0.85, < .001; specificity of 77% vs 66%, < .001), leading to 22.7% fewer biopsies compared with PI-RADS. Sensitivity analyses showed the importance of multiple sequences and vendors in achieving model generalization, as using specific sequences or vendors alone led to worse performance. Fairness analysis showed generalizability across different categories but highlighted increased sensitivity with higher PI-RADS and reduced performance in one medical center. Conclusion A multimodal model provided a temporally generalizable predictor of csPCa that outperformed PI-RADS. Algorithm Development, Machine Learning, Model Validation, Model Training, Genital/Reproductive, Neoplasms-Primary, Oncology, Comparative Studies, Technology Assessment © RSNA, 2025.

Authors

  • Ana Carolina Rodrigues
    Champalimaud Research, Champalimaud Foundation, Computational Clinical Imaging, Av. Brasília, Doca de Pedrouços, Lisboa, Lisbon, PT 1400-038, Portugal.
  • José Guilherme de Almeida
    Champalimaud Foundation, Lisbon, Portugal. jose.almeida@research.fchampalimaud.org.
  • Nuno Rodrigues
    Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal.
  • Raquel Moreno
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Ana Sofia Castro Verde
    Champalimaud Research, Champalimaud Foundation, Avenida Brasilia, Lisboa, Lisboa 1400-038 Portugal.
  • Ana Mascarenhas Gaivão
    Department of Radiology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Carlos Bilreiro
    Department of Radiology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Inês Santiago
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Joana Ip
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Sara Belião
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Sara Silva
    LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal.
  • Inês Domingues
    Instituto Politécnico de Coimbra, Instituto Superior de Engenharia, Rua Pedro Nunes-Quinta da Nora, 3030-199, Coimbra, Portugal.
  • Manolis Tsiknakis
    Computational BioMedicine Laboratory, FORTH-ICS, Heraklion, Crete, Greece.
  • Konstantinos Marias
    FORTH, Institute of Computer Science, Computational BioMedicine Lab, Greece.
  • Daniele Regge
    From the 3D Imaging Research Lab, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 25 New Chardon St, Suite 400C, Boston, MA 02114 (R.T., J.J.N., N.K., T.H., H.Y.); Department of Information Science and Technology, National Institute of Technology, Oshima College, Yamaguchi, Japan (R.T.); Department of Medical Physics and Engineering, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (J.O.); Department of Medical Physics, University of Applied Sciences Giessen, Giessen, Germany (N.K.); Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (S.H.K.); Department of Surgical Sciences, University of Torino, Turin, Italy (D.R.); and Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Turin, Italy (D.R.).
  • Nikolaos Papanikolaou
    Computational Biomedicine Laboratory (CBML), Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece.